NCT05152147 2026-04-17
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT06731478 2026-03-16
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT06532006 2026-02-27
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
Phase 3 Recruiting
NCT07315750 2026-01-21
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02578368 2024-11-12
FLOT5
Krankenhaus Nordwest
Phase 3 Completed
NCT01774786 2020-12-30
JACOB
Hoffmann-La Roche
Phase 3 Completed
NCT01450696 2016-11-28
HELOISE
Hoffmann-La Roche
Phase 3 Terminated
NCT01041404 2014-11-05
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Hoffmann-La Roche
Phase 3 Completed